Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low‐dose regimens
Authors:
- Shih‐Pien TsaiSTShih‐Pien Tsai
- Tai‐Tsung ChangTCTai‐Tsung Chang
- 26 July 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (6) , 1029-1033
Abstract
Background Inhibitory antibodies against infused clotting factor VIII concentrates (FVIII) developed in 20–30% of patients with hemophilia A. Bypass therapy may control the bleeds in patients with FVIII inhibitors, however, immune tolerance induction (ITI) therapy is the only proven modality for eradicating FVIII inhibitors. Since the cost of high-dose (200 IU/kg) ITI is extremely expansive, we conducted this study to identify whether low-dose ITI can be an alternative strategy besides high-dose ITI or bypass therapy. Procedure Patients with hemophilia A and FVIII inhibitors treated by ITI in Kaohsiung Medical University Hospital from January 2000 to January 2010 were enrolled. Regimens of ITI therapy included high-dose (100 IU/kg) and low-dose (30–50 IU/kg). Results High-dose ITI therapy for two high responders (HRs) and low-dose ITI therapy for three HRs and all low responders (LRs) were performed. Complete tolerance was achieved in 2 HRs with high-dose regimen, and in one HR and 19 LRs with low-dose regimens. We administered low-dose ITI combined with immune suppressants treatment for one of the patient with extremely high FVIII inhibitor titers and the inhibitor level markedly declined and no spontaneous bleeding episode was noticed during the treatment period. Conclusions The outcome of ITI in our study was satisfactory without clinically significant complications. Low-dose ITI regimens can effectively treat patients with high responder inhibitors, including one patient with extremely high inhibitor levels over 700 BU. Low-dose ITI may be an alternative modality for FVIII inhibitors management, especially in countries with limited resources. Pediatr Blood Cancer 2011; 57: 1029–1033.Keywords
This publication has 36 references indexed in Scilit:
- The national registry of haemophilia A and B in Spain: results from a census of patientsHaemophilia, 2009
- Haemophilia care then, now and in the futureHaemophilia, 2008
- Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitorsHaemophilia, 2008
- Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysisHaemophilia, 2008
- Factor VIII inhibitor bypassing activity (FEIBA) – addressing safety issuesHaemophilia, 2007
- The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors OrganisationBritish Journal of Haematology, 2006
- Anti-factor VIII antibodiesThrombosis and Haemostasis, 2005
- The International Registry of Immune Tolerance: 1994 UpdateVox Sanguinis, 1996
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIINew England Journal of Medicine, 1988
- MASSIVE FACTOR-VIII INFUSION IN HÆMOPHILIAC WITH FACTOR-VIII INHIBITOR, HIGH RESPONDERThe Lancet, 1977